Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. UPB
stocks logo

UPB

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax
Wall Street analysts forecast UPB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for UPB is 57.50 USD with a low forecast of 40.00 USD and a high forecast of 75.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast UPB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for UPB is 57.50 USD with a low forecast of 40.00 USD and a high forecast of 75.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 27.740
sliders
Low
40.00
Averages
57.50
High
75.00
Current: 27.740
sliders
Low
40.00
Averages
57.50
High
75.00
Evercore ISI
Cory Kasimov
Outperform
initiated
$40
2025-11-18
Reason
Evercore ISI
Cory Kasimov
Price Target
$40
2025-11-18
initiated
Outperform
Reason
Evercore ISI analyst Cory Kasimov initiated coverage of Upstream Bio with an Outperform rating and $40 price target. The firm says the company's sole program verekitug is going after multi-billion dollar indications. Verekitug has a validated mechanism of action, offers a more convenient dosing schedule, and could potentially enable superior efficacy over current thymic stromal lymphopoietin targeting agents, the analyst tells investors in a research note. Evercore believes Upstream's Phase 2 asthma readout in Q1 of 2026 "could be a meaningful upside catalyst."
Truist
Buy
initiated
$47
2025-10-14
Reason
Truist
Price Target
$47
2025-10-14
initiated
Buy
Reason
Truist initiated coverage of Upstream Bio with a Buy rating and $47 price target. Verekitug offers similarly robust efficacy as other TSLP-receptor inhibitors, but with a much improved dosing schedule via targeting the receptor, the analyst tells investors. Given the size of the market and verekitug's value proposition, the firm thinks it could "easily become a mega-blockbuster drug," the analyst added.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Upstream Bio Inc (UPB.O) is -9.00, compared to its 5-year average forward P/E of -5.47. For a more detailed relative valuation and DCF analysis to assess Upstream Bio Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.47
Current PE
-9.00
Overvalued PE
-2.83
Undervalued PE
-8.10

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-4.03
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.30
Undervalued EV/EBITDA
-7.75

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
536.84
Current PS
0.00
Overvalued PS
895.07
Undervalued PS
178.62
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

UPB News & Events

Events Timeline

(ET)
2025-11-05
07:16:24
Upstream Bio Announces Q3 Revenue of $683k, Exceeding Consensus of $516.8k
select
2025-09-30 (ET)
2025-09-30
06:12:59
Upstream Bio's verekitug demonstrates inhibition of TSLP binding in respiratory conditions.
select
2025-09-02 (ET)
2025-09-02
06:04:30
Upstream Bio's verekitug achieves trial objectives in Phase 2 study for rhinosinusitis
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-26TipRanks
Top Analysts Recommend 3 Best Stocks to Purchase Now, 11/26/2025

  • Top Stock Picks: Three companies have received Strong Buy ratings from top Wall Street analysts, indicating significant upside potential for investors.

  • Analyst Tools: TipRanks offers an Analyst Top Stocks tool that tracks real-time Buy ratings from high-performing analysts, helping investors make informed decisions.

  • Analyst Rankings: Financial analysts are ranked by TipRanks based on their rating success rates and average returns, with top analysts achieving five-star rankings for their accuracy and profitability.

  • Research Resources: Investors are encouraged to thoroughly research stocks before adding them to their portfolios, utilizing resources like TipRanks’ Top Wall Street Analysts page for real-time insights.

[object Object]
Preview
8.0
11-21NASDAQ.COM
Purchase Upstream Bio for $20 and Achieve 80.2% Annualized Returns Through Options

  • Put Selling and Upside Potential: Selling a put option does not provide the same upside potential as owning shares, as the seller only acquires shares if the contract is exercised, which occurs if the stock price drops significantly.

  • Risk and Reward Analysis: The potential reward for selling a put option at a $20 strike price is limited to the premium collected, with an annualized return of 80.2%, contingent on the stock price declining to a certain level.

  • Market Activity: Recent trading data shows a put:call ratio of 0.72 among S&P 500 components, indicating a higher volume of put options being traded than historically expected.

  • Volatility Considerations: The historical volatility of Upstream Bio Inc is calculated at 85%, which, along with fundamental analysis, can help assess the risk-reward balance of selling put options.

[object Object]
Preview
4.0
11-18Benzinga
Evercore ISI Group Begins Coverage of Upstream Bio with Outperform Rating and Sets Price Target at $40

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, fostering a collaborative environment for sharing market intelligence.

  • Market Winning Tools: Benzinga Pro equips traders with tools and information designed to improve their chances of success in the markets.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Upstream Bio Inc (UPB) stock price today?

The current price of UPB is 27.74 USD — it has increased 2.86 % in the last trading day.

arrow icon

What is Upstream Bio Inc (UPB)'s business?

Upstream Bio, Inc. is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist in clinical development, that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. It has advanced this highly potent monoclonal antibody into separate phase II trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and plans to initiate development in chronic obstructive pulmonary disease. TSLP is a member of a class of epithelial cytokines, also including IL-25 and IL-33, commonly referred to as alarmins. TSLP is primarily produced by epithelial cells, especially in the lung, gastrointestinal tract and skin.

arrow icon

What is the price predicton of UPB Stock?

Wall Street analysts forecast UPB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for UPB is 57.50 USD with a low forecast of 40.00 USD and a high forecast of 75.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Upstream Bio Inc (UPB)'s revenue for the last quarter?

Upstream Bio Inc revenue for the last quarter amounts to 683.00K USD, increased 12.52 % YoY.

arrow icon

What is Upstream Bio Inc (UPB)'s earnings per share (EPS) for the last quarter?

Upstream Bio Inc. EPS for the last quarter amounts to -0.63 USD, increased 53.66 % YoY.

arrow icon

What changes have occurred in the market's expectations for Upstream Bio Inc (UPB)'s fundamentals?

The market is revising Downward the revenue expectations for Upstream Bio, Inc. (UPB) for FY2025, with the revenue forecasts being adjusted by -1.88% over the past three months. During the same period, the stock price has changed by 38.91%.
arrow icon

How many employees does Upstream Bio Inc (UPB). have?

Upstream Bio Inc (UPB) has 52 emplpoyees as of December 05 2025.

arrow icon

What is Upstream Bio Inc (UPB) market cap?

Today UPB has the market capitalization of 1.50B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free